Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Excessive Daytime Somnolence Clear all
Completed Phase 4 Interventional Results available

Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy

NCT01190098
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Lacosamide, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Results available

A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

NCT05875974
View directory record Official record
Conditions
Idiopathic Hypersomnia, Narcolepsy
Interventions
JZP258 (XYWAV)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Terminated Not applicable Interventional

Whole Food Plant-based Diet Effect on Obstructive Sleep Apnea

NCT06395181
View directory record Official record
Conditions
Obstructive Sleep Apnea, Daytime Sleepiness
Interventions
Whole Food Plant-Based Diet
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Light Exposure to Treat Sleep Disruption in Older People

NCT00427323
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Circadian Rhythm Sleep Disorders, Hypersomnia
Interventions
light exposure
Procedure
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Sep 30, 2026, 4:14 AM EDT
Recruiting Phase 3 Interventional

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217
View directory record Official record
Conditions
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MG, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • Bellflower, California • Chino, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

NCT07540897
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Brandon, Florida • Miami, Florida • Winter Park, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional Results available

Light Therapy Treatment in Parkinson's Disease Patients With Daytime Somnolence

NCT01338649
View directory record Official record
Conditions
Parkinson's Disease, Sleep Disorder; Excessive Somnolence
Interventions
Bright Light Treatment (Sun Ray Sunbox SB-558), Dim red light (Sun Ray Sunbox SB-558)
Device
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 30, 2026, 4:14 AM EDT
Recruiting Phase 3 Interventional

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06366464
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Pitolisant tablet, Placebo tablet
Drug · Other
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
6 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does myTAP Oral Appliance Therapy Including a Mouth Shield Lessen Periodontitis in Mouth-Breathers Who Snore?

NCT06797089
View directory record Official record
Conditions
Snoring, Mouth Breathing, Daytime Sleepiness, Periodontitis
Interventions
Oral appliance therapy plus scaling and root planing on left or right of mouth
Device
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community-Level Daytime Sleepiness: Social-Environmental Determinants, Consequences, and Impact of Sleep Apnea

NCT04176042
View directory record Official record
Conditions
Daytime Sleepiness
Interventions
Track 1, Track 2
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
20 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 3 Interventional

A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia

NCT05458128
View directory record Official record
Conditions
Idiopathic Hypersomnia, Excessive Daytime Sleepiness
Interventions
Pitolisant
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
32
States / cities
Los Angeles, California • San Ramon, California • Brandon, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease

NCT01742182
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Light exposure
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 30, 2026, 4:14 AM EDT
Recruiting Phase 2 Interventional

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

NCT07096674
View directory record Official record
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ORX750
Drug
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
19
States / cities
Auburn, Alabama • Santa Ana, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

NCT00066170
View directory record Official record
Conditions
Narcolepsy
Interventions
Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Sep 30, 2026, 4:14 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder

NCT04788953
View directory record Official record
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol Oral Tablet, Placebo
Drug
Lead sponsor
Charles A. Czeisler, PhD, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 30, 2026, 4:14 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

NCT06843590
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
ALKS 2680, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
34
States / cities
Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Project REST: Club Sports

NCT07103759
View directory record Official record
Conditions
Poor Quality Sleep
Interventions
Refrain from caffeine techniques, Project REST Platform
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 30, 2026, 4:14 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)

NCT07500090
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
HBS-301 tablet, Placebo
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Birmingham, Alabama • Peoria, Arizona • Redwood City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

NCT04072380
View directory record Official record
Conditions
Narcolepsy
Interventions
SUVN-G3031, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

NCT04886518
View directory record Official record
Conditions
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Interventions
Pitolisant Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Not applicable Interventional Results available

Bright Light Therapy for Residual Daytime Symptoms Associated With Obstructive Sleep Apnea

NCT04299009
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Bright light therapy glasses
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

NCT00228553
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, Chronic Shift Work Sleep Disorder
Interventions
Armodafinil 100 to 250 mg/day
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

NCT04923594
View directory record Official record
Conditions
Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy
Interventions
mazindol extended release, Placebo
Drug
Lead sponsor
NLS Pharmaceutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Sep 30, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

NCT04091425
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
TAK-925, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 30, 2026, 4:14 AM EDT